Drug intelligence / Profile preview

InViVoCAR1920 mRNA

Development stage: Phase 2
Lead developer: Daihong Liu
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

InViVoCAR1920 mRNA is an experimental *in vivo* CAR-T cell therapy being developed for the treatment of relapsed or refractory B-cell lymphoma and leukemia. The therapy utilizes polymer-lipid nanoparticles (PLNs) to deliver mRNA encoding a dual-targeting chimeric antigen receptor (CAR) that simultaneously targets CD19 and CD20 antigens on the surface of malignant B cells. Unlike conventional CAR-T therapies that require complex *ex vivo* genetic modification of a patient's T cells, InViVoCAR1920 mRNA is designed to reprogram T cells directly within the patient's body. This approach aims to simplify the manufacturing process, reduce treatment wait times, and mitigate the risk of antigen escape by targeting two distinct B-cell markers.

Other names: CD19/CD20 dual-targeting InViVoCAR1920 mRNAPolymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoCAR1920 mRNA

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on InViVoCAR1920 mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InViVoCAR1920 mRNA.

Explore the full profile